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INTRODUCTION
HYPOKALAEMIA is known to occur in patients receiving long-term carbenoxolone
therapy. (Brown et al., 19,72). Though the loss of potassium with normal dosage
rarely produces symptoms, several case reports of patients with muscle paresis and
myopathy have appeared. (Mohamed et al., 1966; Forshaw, 1969; Swallow, 1969;
Mitchell, 1971). We report a case of unusual severity.
CASE REPORT
A 48 year old man was admitted with a four-day history of muscle cramps and
paralysis. Two months previously the patient had been treated in another hospital
for haematemesis arising from a lesser-curve gastric ulcer. At that time the serum
potassium was 3.44 m.Eq/ 1. He received 6 units of whole blood. Five days later
carbenoxolone sodium 150 mg daily was commenced. No other drugs were
prescribed. He took carbenoxolone for 28 days, and 7 days after discontinuing the
drug he was reviewed at the first hospital. He reported no symptoms but had
gained 10.1 Kg in five weeks. Later that day he developed cramps in his thighs and
experienced difficulty in walking owing to weakness in his back and legs. The
weakness got worse over the four days preceding admission to this hospital, until
he could not lift his head from the pillow.
On examination there was complete paralysis of the extensors of the left wrist,
severe weakness of the left biceps, triceps and deltoid muscles and marked winging
of the left scapula. The right arm and both legs were less severely affected but
there was almost complete paralysis of the sternomastoid and trapezius muscles.
Ocular movements, speech and swallowing were normal. The tendon reflexes were
absent in the left arm but present in the other limbs. The plantar responses were
flexor. There was no muscle wasting but stretching of both quadriceps groups
caused pain. Sensation was normal. The blood pressure was 160/100 mm.Hg:
there was no oedema.
Investigations on admission were as follows: The serum electrolytes (m.Eq/1)
were: sodium 149, potassium 2.19, chloride 91, CO2 > 40, Astrup: pH 7.55,
PCO2 53, base excess > +20, plasma bicarbonate 46. The Hb was 11.4 gm%,
white cells 7,000/c.mm., and the serum proteins 6.85 gm%. Serum calcium was
8.5 mg%/, and phosphorus 2.05 mg%. The serum creatine phosphokinase was 1,100
units/ml (normal 0-50 units/ml). The urine was alkaline and slightly smoky in
appearance. There was a trace of albuminuria and microscopical examination
84showed somie red cells and a few organisms. No porphyrins were detected.
Spectroscopic examination for myoglobin was not performed. The cardiogram
showed marked hypokalaemic changes with ST segment depression, massive U
waves and frequent ventricular ectopic beats.
He received 250 m.Eq of potassium by intravenous infusion over 36 hours, by
which time the serum potassium had risen to 2.63 m.Eq/ I and the patient felt much
stronger. Oral potassium, 160 m.Eq/day in tablet form was commenced. On the
sixth day of treatment, when recovery of muscle power was almost complete, serum
potassium was 3.5 m.Eq/1, C02, 39 m.Eq/I and serum creatine phosphokinase
670 units/mi. His potassium intake and blood levels are illustrated in the Figure.
400
300
TOTAL
POTASSIUM
INTAKE 200
INCLUDING
DIET
SERUM POTASSIUM RELATED TO POTASSIUM INTAKE
0 4
0 5 10
*4
SERUM
3 POTASSIUM
mEq/L
2
0
15
DAYS FOLLOWING ADMISSION
Figure relating inttake of potassium to correction of serum potassium.
At review two weeks later no paresis remained. The blood pressure was 140/80
mm.Hg and the patient had lost 5.4 Kg since discontinuing carbenoxolone. The
serum electrolytes (m.Eq/l) were: sodium 144, potassium 4.65, chloride 103 and
CO2 32.1. The cardiogram was normal. Potassium supplements were discontinued.
Three months later the electrolytes were normal, serum creatine phosphokinase
was 8 units/ml and the serum aldolase 1.4 units/ml. The serum calcium was 10.0
mg%/,, phosphorus 3.8 mg%/, and serum proteins 6.3 gmr/0.
COMMENT
The onset of paralysis after only 4 weeks treatment with Carbenoxolone is most
unusual. Mitchell (1971) reported the onset of paralysis after five weeks treatment
in a patient on a higher dosage (200 mg. daily). The severity of potassium depletion
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100 tin our patient was remarkable. Based on replacement requirements more than one
third of total body exchangeable potassium had been lost i.e. 30-40 m.Eq/day for
four weeks (Figure). This is comparable to the severity of potassium loss in the
case of Mohamed et al. (1966). We cannot explain the long interval between
cessation of treatment and the onset of weakness. Though Duogastrone may remain
in the stomach for several days, Biogastrone is absorbed rapidly. Delayed paralysis
was not precipitated by the administration of a thiazide diuretic as in the case of
Fyfe et al. (1969). Swallow (1969) described a patient with weakness of the neck
muscles but we have not discovered another case with complete "head-drop".
Muscle pain is often a more prominent feature than in the present case and may
be the dominant symptom (Morgan et al. 19,66). Mohamed et al. (1966) demon-
strated myositis in patients with muscle pain and weakness. In the case of Swallow
(1969), the electromyogram was consistent with a myopathic lesion although the
muscle pain and tenderness were absent. The very high levels of creatine phos-
phokinase suggest that myositis occurred in the present case.
Flaccid paralysis with profound hypokalaemia due to carbenoxolone therapy
has been attributed to an aldosterone-like metabolic action of the drug (Baron and
Nabarro 1967). Much of this patient's substantial weight gain and rise in blood
pressure during treatment must have been due to fluid retention, a conclusion
supported by the rapid weight loss and the return to normal of the blood pressure
after discontinuation of the drug. Retention of sodium and water is accompanied
by an increased excretion of potassium. The alkalosis is thought to be due to a
physiological attempt to conserve potassium ions by the excretion of ammonium
ions.
The present case emphasises the need for careful monitoring of the weight, blood
pressure and serum potassium of all patients receiving Carbenoxolone. In view of
the potentially lethal effects of severe hypokalaemia it would seem prudent to
administer potassium 40 m.Eq daily to such patients.
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